COVID-19: Drugs in Development


The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Current Stage
Next Milestone
Last Updated
AB Science SA
Phase 2 study in Covid-19 treatment.
--On June 1, 2021, temporarily paused Phase 2 study, after identifying a potential risk of ischemic heart disease with masitinib.
--On July 12, 2021, the measures proposed by AB Science to reinforce patient safety in masitinib trials were accepted by French National Agency.
--On Sept. 16, 2021, received clearance from the Russian Health Ministry to resume patient enrollment in the phase 2 study.
CalciMedica Inc.
Phase 2 study in hospitalized patients with COVID-19 pneumonia (CARDEA)
Results reported from CARDEA on Sep.14, 2021, suggest that Auxora may rapidly reduce inflammation and reduce damage to vital organ tissue
RedHill Biopharma Ltd.
Global Phase 2/3 study of Opaganib in patients hospitalized with severe SARS-CoV-2 infection

-- On Jan.29, 2021, Data Safety Monitoring Board (DSMB) recommended that the study continue following a pre-scheduled futility review.
--On Sept. 14, 2021, topline data from the Phase 2/3 study of opaganib in hospitalized patients with severe COVID-19 pneumonia were reported, that did not meet primary endpoint.
Top-line data and potential global emergency use authorization applications are expected in the second quarter of 2021
RedHill Biopharma Ltd.
FDA has cleared Phase 2/3 study of orally administered RHB-107 in patients with symptomatic COVID-19 who do not require hospitalization.
--On Sep 14, 2021, announced acceleration of the ongoing Phase 2/3 study of RHB-107, with clearance to start the trial in South Africa. The number of study sites in the United States has also been expanded.
Preclinical study
Institut Pasteur
Swedish Orphan Biovitrum
Phase 3
On Sept.7, 2021, positive results were published in "Nature Medicine" from the Phase 3 study of anakinra, dubbed Save-more, in hospitalized adult patients with COVID-19 pneumonia.
Entos Pharmaceuticals
Covigenix VAX-001
On Sept. 1, 2021, received approval to start Phase 2 study in South Africa after meeting all safety endpoints in Phase 1 study.
NRx Pharmaceuticals, Inc.
Inhaled Zyesami in Phase 2 study dubbed I-SPY for the treatment of severely and critically ill COVID-19 patients.

--Inhaled Zyesami in Phase 2b/3 study dubbed AVICOVID-2 for the treatment of severe COVID-19 with respiratory failure.
Quantum Leap Healthcare Collaborative, Biomedical Advanced Research and Development Authority (BARDA)

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
Twitter has rolled out the tipping feature called "Tips" for everyone around the globe using the microblogging site with more payment options to choose from, including cryptocurrencies such as Bitcoin. This is a new way for people to receive and show support on Twitter with money. The feature is currently available on iOS and will be available on Android over the coming weeks. Amazon.com has launched weekly Max-Your-Vax Sweepstakes to encourage their employees to get vaccinated against COVID-19. The sweepstakes began on August 6, 2021 and ends on October 21, 2021, with six draws during the sweepstakes period for 18 prizes worth nearly $2 million, including cash prizes, new vehicle or cash and vacation plus 40 hours of Paid Time Off. Target Corp. announced its plans to hire 100,000 seasonal team members at its stores across the country for this holiday shopping season, though fewer than previous years. With this, the company aims to invest in more flexible scheduling, training, pay and benefits for its existing team members. In a statement, the company said it is also offering around 5 million more hours to its existing staff.